论文部分内容阅读
目的检测分析骨转移为首发的非小细胞肺癌中ER-β的表达,分析其与临床预后相关性。方法应用免疫组织化学方法检测经病理证实骨转移为首发的非小细胞肺癌肿瘤组织标本中ER-β的表达,利用χ2检验检测组间表达差异,生存率单因素采用Kaplan-Meier法及Log-rank方法分析,多因素采用COX回归模型进行分析。结果 46例骨转移为首发的非小细胞肺癌中ER-β总阳性78.3%,χ2检验未见性别、年龄、病理类型、骨转移灶数目、有无骨外其他部位转移、ALK及CEA影响ER-β表达,各组阳性率差异无统计学意义。多因素分析显示ER-β为影响该类患者预后的独立影响因素(P=0.035),单因素分析可见ER-β阳性表达组的生存时间明显长于阴性表达组,差异有统计学意义(P<0.05)。另外ER-β阳性表达时腺癌、单发骨转移患者能获得较长的生存时间,差异有统计学意义(P<0.05)。结论骨转移为首发的非小细胞肺癌ER-β表达阳性率高,ER-β阳性表达的患者预后明显好于阴性患者,且其可能为影响患者预后的独立影响因素,ER-β的阳性表达可能与腺癌及单发骨转移患者的预后相关。
Objective To detect and analyze the expression of ER-β in non-small cell lung cancer (NSCLC) with bone metastasis as the first test, and to analyze its correlation with clinical prognosis. Methods Immunohistochemistry was used to detect the expression of ER-β in non-small cell lung cancer specimens with pathologically confirmed bone metastases. The expression of ER-β was detected by χ2 test. Kaplan-Meier method and Log- rank method analysis, multi-factor analysis using COX regression model. Results The total positive rate of ER-β in 46 cases with primary bone metastasis was 78.3%. There was no gender, age, pathological type, number of bone metastases, metastasis of other sites with or without bone metastasis, ALK and CEA -β expression, the positive rate of each group was no significant difference. Multivariate analysis showed that ER-β was an independent factor affecting the prognosis of these patients (P = 0.035). Univariate analysis showed that the survival time of ER-βpositive expression group was significantly longer than that of negative expression group (P < 0.05). In addition ER-β-positive adenocarcinoma, single bone metastasis patients can get a longer survival time, the difference was statistically significant (P <0.05). Conclusions The positive rate of ER-β expression in non-small cell lung cancer with bone metastases is high. The prognosis of patients with positive ER-β expression is significantly better than that of negative patients. And it may be an independent factor affecting the prognosis of patients. The positive expression of ER-β It may be related to the prognosis of patients with adenocarcinoma and single bone metastases.